anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PCT No. PCT/FR96/02008 Sec. 371 Date Jun. 15, 1998 Sec. 102(e) Date Jun. 15, 1998 PCT Filed Dec. 13, 1996 PCT Pub. No. WO97/21828 PCT Pub. Date Jun. 19, 1997A process is provided for the production of glycogens or an extract rich in glycogens from yeast cells, and a cosmetic composition containing them. A given quantity of yeast cells, from a specific culture or recovered as residues of a fermentation process, is subjected to an operation of enrichment in intracellular glycogens by culturing in two phases in the presence of a carbon source. The metabolism of the yeast cells is then stopped. The membranes of the yeast cells are then at least partially disintegrated to free intracellular substances, and the freed intracellular substances are subjected to at least one precipation to precipitate glycogens. A cosmetic composition comprising the glycogens is formulated in admixture with a dermatologically acceptable excipient.
The present invention provides an inhalation-type pharmaceutical composition for arthritis and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising indomethacin, flurbiprofen, celecoxib, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can remove harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user.
PURPOSE:To improve observation shadow reading of a medical image, and a diagnostic function by providing information for determining a relative image display position on the medical image, and relating the photographing direction and a photographing means of the medical image in a specific examination of a body to be examined, and the relative image display position. CONSTITUTION:Image data of a medical image generated by an image collecting device 11, and its examination information and image incidental information are stored in a data base (DB) 12. Subsequently, when a patient's ID number is inputted from an input device 36 of a work station (WS) 13. Its ID is sent out to the DB 12, and the DB 12 transfers desired inspection information to the WS 13. Next, the WS 13 displays the inspection information as a patient's examination history to a character display device 37. In such a state, when an examination for shadow reading is designated, image incidental information and image data of a shadow reading object examination are transferred to the WS 13 from the DB 12. Subsequently, by a display position specifying means in an examination information/image incidental information storage device 39, a display position of each medical image is determined and displayed on an image display device 38.
Transforming growth factor beta (TGFβ) signaling plays a critical role in tumorigenesis and metastasis. However, little is known about the biological function of TGFbeta-induced lncRNA in cancer. In this study, we discovered a novel TGFbeta-induced lncRNA, termed TGILR, whose function in cancer remains unknown to date. TGILR expression was directly activated by the canonical TGFbeta/SMAD3 signaling axis, and this activation is highly conserved in cancer. Clinical analysis showed that TGILR overexpression showed a significant correlation with lymph node metastasis and poor survival and was an independent prognostic factor in gastric cancer (GC). Depletion of TGILR caused an obvious inhibitory effect on GC cell proliferation, invasion, and epithelial-mesenchymal transition (EMT) in vitro and in vivo. More importantly, we demonstrated that TGFbeta signaling in GC was overactivated due to cancer-associated fibroblast (CAF) infiltration. Mechanistically, increased level of CAF-secreted TGFbeta activates TGFbeta signaling, leading to TGILR overexpression in GC cells. Meanwhile, TGILR overexpression inhibited the microRNA biogenesis of miR-1306 and miR-33a by interacting with TARBP2 and reducing its protein stability, thereby promoting GC progression via TCF4-mediated EMT signaling. In conclusion, CAF infiltration drives GC metastasis and EMT signaling through activating TGFbeta/TGILR axis. Targeted blocking of CAF-derived TGFbeta should be a promising anticancer strategy in GC.
Prior to the oocyte pick up (OPU) procedure, the dimensions (height x width x depth) of the first accessible follicle in any ovary will be recorded in millimeters. In this regard, any follicle larger than 12 mm will be selected for the first aspiration. It is planned to evaluate the effectiveness of the washing process in follicles with different sizes by performing the first aspiration procedure regardless of the follicle size. After aspiration of all the follicle fluid with a double lumen needle (17 Gauge), the remaining fluid in the needle and line will be aspirated by giving 2 cc "flushing medium" to the follicle. In this way, all of the pure follicle fluid will be delivered to the in vitro fertilization (IVF) laboratory with the OPU tube for initial evaluation. After the evaluation, if no cumulus oocyte complex (COC) is observed in the first sample, the washing process will be started. In this regard, flushing and aspiration will be performed respectively by giving 2 cc "flushing medium" to the same follicle 3 times. A total of 6 cc flushing medium obtained after the flushing-aspiration process will be delivered to the IVF laboratory and the presence of COC in it will be investigated again under the microscope. Depending on the retrieval of oocyte by direct aspiration or flushing, each oocyte will be followed individually and its quality will be evaluated in case of embryo development from this oocyte.
An infusion preparation for peripheral parenteral administration comprises infusion preparation (A) which contains glucose by concentration of 80-200g/L and infusion preparation (B) which contains an aminoNacid by concentration of 50-150g/L. The infusion preparation (A) and the infusion preparation (B) are each separately put into a vessel divided with the open able partition means. The infusion preparation (A) does not contain sulfite, its titgratable acidity is one or less. Further, the infusion preparation (A) contains vitamin B1 and is adjusted to pH 3-5. The infusion preparation (B) is adjusted to pH 6.5-8. Further, pH after mixing both infusion preparation are 6-7.5, and titratable acidity is 5-10.
Data representative of operation of biomedical equipment in a medical facility is collected and stored in a centralized database. The information may be collected manually during the life of the equipment, or automatically by connection to the equipment. The data references equipment types, manufacturer, departments, locations, and other relevant information for the equipment. Based upon the collected and stored information, parameters representative of possible training needs is analyzed and reported. The parameters may include error, breakdowns, and the like. Detailed reports delivered to the medical institution may thus provide a basis for planning training to enhance performance and utilization of the equipment.
The distal end of the duodenum was closed. The jejunum was separated 15-20cm distal to the Treitz's ligament, and an end-to-side esophagojejunostomy was done at the distal side of the jejunum. Then, the continuity of the jejunum was reconstructed with side-to-end jejunojejunostomy at 40-45cm distal to esophagojejunostomy.
Buprenorphine is metabolized to norbuprenorphine by cytochrome CYP 3A4. Because CYP 3A4 inhibitors may increase plasma concentrations of buprenorphine, patients already on CYP 3A4 inhibitors such as azole antifungals (e.g. ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.

Based on anecdotal reports, there may be an interaction between buprenorphine and benzodiazepines. There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of buprenorphine and benzodiazepines by addicts. In many of these cases, buprenorphine was misused by self-injection of crushed SUBUTEX tablets. SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse. Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.
FIELD: medicine. ^ SUBSTANCE: invention concerns a pharmaceutical agent in the form of a solution for injections containing Mexidol, sodium metabisulphite as a preserving agent which can be used for treating an acute myocardial infarction, vegetovascular dystonia, psychosomatic and some other diseases. The pharmaceutical agent exhibits high storage stability provided a pH value of the solution is maintained at 4.2-4.4. Preferentially, the pharmaceutical agent is packed in dark glass ampoules of nominal volume 2 ml or 5 ml. ^ EFFECT: improved properties of the pharmaceutical agent. ^ 3 ex
The first 12 patients to be enrolled will initiate therapy with CDX-1401 alone, with the addition of MPDL3280A the day of their 4th CDX-1401 vaccination (week 7). These patients will undergo a tumor biopsy prior to initiation of trial therapy, after their 3rd CDX-1401 vaccination (during week 6) and after their 3rd MPDL3280A infusion (during week 14 or 15, if there are no dose delays). Although we don't expect significant synergistic toxicities of combination therapy based on mechanism of action/ formulation/ administration/ distribution of CDX-1401 and past vaccine/ immune checkpoint trials, these first 12 patients will constitute a safety run in group.
Participants will receive VLNC (very low nicotine cigarettes) with the lowest nicotine dose (.03 mb nicotine yield). Participants will also receive the generic ("Clearing the Air") materials, as well as one-on-one counseling.
Those receiving ONS will be prescribed a standard ONS (1.0 kcal per mL) that will meet a minimum of 50% of estimated energy needs to promote weight gain but allow for continued regular dietary intakes. The ONS will be prescribed as 8oz (240mL) per dose at least once a day, but up to six times per day depending on estimated nutrient needs.
Giggle incontinence (GI) is poorly described, defined, and understood. It is considered a bladder storage disorder in which laughter causes an uncontrollable episode of urinary incontinence that cannot be stopped until the bladder is completely emptied. It has been confused with stress urinary incontinence and overactive bladder. A thorough analysis of 26 articles on the subject of "giggle incontinence" and associated terms was performed, including all articles since the phrase first appeared. To date, 351 GI cases have been reported. It occurs mainly in women (69.5%) at 5 years of age, with a prevalence ranging from 8.4 to 16.2 years (average age of 12.4 years), and some cases have a family history of the disease (13-16.7%). This review discusses the historical background, current understanding, and challenges related to GI. It primarily affects females after the age of 5 years, causing complete bladder emptying during uncontrollable laughter. The exact cause is unknown, but hypotheses suggest involvement of the central nervous system. Diagnosis relies on clinical history, physical tests, and urine frequency evaluation. Management involves urotherapy techniques, biofeedback, and methylphenidate. Understanding GI will aid in developing more effective management techniques. IMPACT: Highlights limited awareness among healthcare professionals about giggle incontinence as a distinct condition, emphasizing the need for standardized diagnostic criteria and assessment tools. Addresses insufficient understanding of the underlying mechanisms and contributing factors, providing valuable insights for better diagnosis and treatment. Emphasizes the importance of patient education and support, calling for improved resources and counseling. Urges further research and evidence-based guidelines to enhance treatment strategies.
A total of 70 patients were included in the study. Using simple randomization method, the patients were acknowledged about the aim of the study and the cards with letters C (control) and S (study) were placed in closed envelopes and the patients were asked to draw a random envelope. After the draw, two groups were formed according to the letter as group I consisted of patients with C letter and group II consisted of patients with S letter.
The intervention to be administered is the eSHAM system used in conjunction with the MagVenture MagProx100 Stimulator with the Cool-B65 A/P Coil. For eSHAM administration two Thymapad Stimulus Electrodes will be placed on the scalp location that corresponded to left DLPFC. This intervention method will be used for all 15 treatment sessions (20 minutes/session). Previous studies have shown the eSHAM system effectively blinds participants to rTMS treatment (active versus sham).
A course of treatment every 21 days. For patients with disease control (CR+ PR+SD) and tolerable adverse reactions after 6 courses of treatment, continuous drug use was considered by the researchers as inappropriate for patients to continue drug use or when the efficacy was assessed as disease progression (PD).No other antitumor treatment can be given during the treatment.
A biscuit containing Kothala Himbutu (Salacia reticulata) extract. This biscuit is available in the supermarkets. Four biscuits twice a day for 3 months.
Tatton-Brown-Rahman syndrome (TBRS) or DNMT3A-overgrowth syndrome is characterized by overgrowth and intellectual disability associated with minor dysmorphic features, obesity, and behavioral problems. It is caused by variants of the DNMT3A gene. We report four patients with this syndrome due to de novo DNMT3A pathogenic variants, contributing to a deeper understanding of the genetic basis and pathophysiology of this autosomal dominant syndrome. Clinical and magnetic resonance imaging assessments were also performed. All patients showed corpus callosum anomalies, small posterior fossa, and a deep left Sylvian fissure; as well as asymmetry of the uncinate and arcuate fascicles and marked increased cortical thickness. These results suggest that structural neuroimaging anomalies have been previously overlooked, where corpus callosum and brain tract alterations might be unrecognized neuroimaging traits of TBRS syndrome caused by DNMT3A variants.
Reference genes are used as internal reaction controls for gene expression analysis, and for this reason, they are considered reliable and must meet several important criteria. In view of the absence of studies regarding the best reference gene for the analysis of acute leukemia patients, a panel of genes commonly used as endogenous controls was selected from the literature for stability analysis: Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Abelson murine leukemia viral oncogene human homolog 1 (ABL), Hypoxanthine phosphoribosyl-transferase 1 (HPRT1), Ribosomal protein lateral stalk subunit P0 (RPLP0), β-actin (ACTB) and TATA box binding protein (TBP). The stability of candidate reference genes was analyzed according to three statistical methods of assessment, namely, NormFinder, GeNorm and R software (version 4.0.3). From this study's analysis, it was possible to identify that the endogenous set composed of ACTB, ABL, TBP and RPLP0 demonstrated good performances and stable expressions between the analyzed groups. In addition to that, the GAPDH and HPRT genes could not be classified as good reference genes, considering that they presented a high standard deviation and great variability between groups, indicating low stability. Given these findings, this study suggests the main endogenous gene set for use as a control/reference for the gene expression in peripheral blood and bone marrow samples from patients with acute leukemias is composed of the ACTB, ABL, TBP and RPLP0 genes. Researchers may choose two to three of these housekeeping genes to perform data normalization.
PROBLEM TO BE SOLVED: To provide a pharmaceutical composition comprising an enantiomeric equol compound used for the treatment of a disease or body abnormality in mammal and human.SOLUTION: The present invention relates to the composition consisting of S-equol, R-equol, or mixtures including non-racemic body and racemic body of equol having chemical structures shown in FIG. 1. The composition can be used to produce commercial items, such as food supplements, pharmaceutical preparations, and pharmaceutical compositions. The compositions are useful in a method of administering S-equol to the mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer is produced in a biological synthesis from the metabolism of an isoflavone by an organism. The method is administered so as to produce a level of R-equol in the blood plasma of the mammal of 5 ng/mL or greater, or so as to produce a level of R-equol in urine of 1000 mol/L or greater.SELECTED DRAWING: Figure 1
Compositions, methods and kits for inhibit-ing a cerebral neurovascular disorder or a mus-cular headache in a human patient are disclosed. Also disclosed are uses of a long-acting local anesthetic ingredient for manufacturing a medica-ment comprising the long-acting local anesthetic ingredient for use in inhibiting a cerebral neu-rovascular disorder in a human patient. The meth-ods comprise intranasally administering to the pa-tient a pharmaceutical composition comprising a local anesthetic, and preferably a long-acting lo-cal anesthetic ingredient. A composition use-ful for practicing the methods of the invention is described which comprises at least one local anesthetic in a pharmaceutically acceptable car-rier, wherein the composition is formulated for intranasal delivery. Cerebral neurovascular disor-ders include migraine and cluster headache. Mus-cular headaches include tension headaches and muscle contraction headaches. A kit comprising the composition and an intranasal applicator and a method of systemically delivering a pharmaceu-tically active agent to an animal are also included in the invention.
A method and computer program product is provided that, in various embodiments, may provide a measure of efficiency of resources used in medical treatment plan options. A normalized Relative Resource Value (RRV) may be obtained that measures the level of resources required to satisfy a “normal” case for a particular aspect of medical care. Applying this value against actual costs allows ranking and/or comparison of health care providers relative to one another on the basis of the price or resources applied or utilized. Moreover, applying the RRV against the quality of outcome allows comparison and ranking of providers on overall value. The invention may be applied to the components of medical care comprising, inter alia, acute inpatient, non-acute inpatient, outpatient, professional office-based care including scheduled outpatient, and pharmacy/prescriptions. The normalized RRV obtained under various embodiments of the invention may measure resource use for medical treatment plan options/resources independent of price. The RRV may be relative across, as well as within, each of the components of medical care. Thus, provider profiling generally as well as profiling across treatment plan options based on efficiency generally is within the scope of various embodiments of the invention. Moreover, providers may be compared based on efficiency for specific conditions, as well as across conditions, across treatment plan options and across components of care using various embodiments of the invention.
BACKGROUND: Cystic echinococcosis (CE) is a zoonotic disease with an Africa-wide prevalence of 1.7%. CE is caused by the tapeworm Echinococcus granulosus sensu lato, with the liver being the most commonly affected organ. In South Africa (SA), there is a paucity of data on liver CE demographics and management.
OBJECTIVES: To describe the demographics and clinical profile of patients with liver CE in a single tertiary hospital in Eastern Cape Province, SA.
METHODS: A 4-year (2019 - 2022) retrospective clinical record review study was conducted on patients presenting with liver CE to the Department of Surgery at Frere Hospital. The demographics, clinical characteristics and management of patients with liver CE are reported.
RESULTS: A total of 56 patients diagnosed with and managed for liver CE were included in the study. The mean age of the patients was 37.5 years. Abdominal pain (n=39; 69.6%) was the most common presenting symptom, and a palpable abdominal mass (n=36; 64.3%) was the predominant presenting sign. Most patients had disease confined to the liver (n=35; 62.5%). The right lobe of the liver was most commonly affected (n=38; 67.9%), and most patients had a single liver cyst on imaging (n=32; 57.1%). The majority of the patients (n=36; 64.3%) were managed with surgical partial cystectomy, with a perioperative bile leak being the most common complication.
CONCLUSION: In our setting, liver CE contributes to a significant local burden of the disease. The disease often has a nonspecific clinical presentation, necessitating imaging for the diagnosis. We observed good short-term outcomes in patients managed with combined partial cystectomy and medical therapy, although there is a risk of perioperative bile leak.
Swedish massage session of 60 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 720 minutes.
OBJECTIVE: To describe the technique for surgeon-administered, ultrasound-guided transversus abdominis plane (SU-TAP) blocks performed during radical cystectomy as a component of multimodal, perioperative pain management.
METHODS: Retrospective, case series of patients receiving SU-TAP blocks just prior to incision for RC. TAP blocks were performed by the surgeon with a standard technique using US guidance to instill an anesthetic solution. The primary outcome was opioid consumption at the intervals of 0-12, 12-24, 24-36, and 36-48 h postoperatively. Opioid consumption was reported as oral morphine milligram equivalents (MME). Secondary outcomes included time to perform SU-TAP blocks, and safety of block procedure.
RESULTS: 34 patients were included. During the median length of stay of 4 days (interquartile range [IQR] 3-7), only 30/34 (88%) of patients required opioids within the first 12 h post-op, decreasing to 38% by 48 h post-op. The median consumption decreased in the first 48 h from 21 MMEs (IQR 9-38) to 10 MMEs (IQR 8-15) at the 0-12 and 36-48 h intervals, respectively. The median time to perform block procedure was 6 min (IQR 4-8 min) and there were no safety events related to the SU-TAP blocks. Limitations include no comparative arm for opioid consumption.
CONCLUSION: Our data suggest that urologists may feasibly perform US-guided TAP blocks as a practical, efficient, and safe method of regional anesthesia. SU-TAP blocks should be considered in ERAS protocols for RC. Future comparative studies on opioid consumption compared to local infiltration and alternative block techniques are warranted.
Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.